Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
Emergent BioSolutions (NYSE:EBS) has scheduled its second quarter 2025 financial results conference call for August 6, 2025, at 5:00 PM ET. The company will provide access to the call through multiple channels, including a live webcast available on their Investors webpage.
Telephone participants must pre-register through a provided link to receive dial-in information and unique access credentials. A replay of the conference call will be made available on the company's Investors page after the event.
Emergent BioSolutions (NYSE:EBS) ha programmato la conference call per i risultati finanziari del secondo trimestre 2025 il 6 agosto 2025, alle 17:00 ET. L'azienda offrirà l'accesso alla chiamata attraverso diversi canali, incluso un webcast in diretta disponibile sulla pagina Investors.
I partecipanti telefonici devono pre-registrarsi tramite un link fornito per ricevere le informazioni di accesso e le credenziali uniche. Una registrazione della conference call sarà disponibile sulla pagina Investors dell'azienda dopo l'evento.
Emergent BioSolutions (NYSE:EBS) ha programado su conferencia telefónica de resultados financieros del segundo trimestre de 2025 para el 6 de agosto de 2025 a las 5:00 PM ET. La compañía ofrecerá acceso a la llamada a través de varios canales, incluyendo una transmisión en vivo disponible en su página de Inversores.
Los participantes telefónicos deben pre-registrarse mediante un enlace proporcionado para recibir la información de marcación y credenciales únicas. Una repetición de la conferencia estará disponible en la página de Inversores después del evento.
Emergent BioSolutions (NYSE:EBS)는 2025년 2분기 재무 실적 컨퍼런스 콜을 2025년 8월 6일 오후 5시(동부 시간)에 예정했습니다. 회사는 투자자 웹페이지에서 라이브 웹캐스트를 포함한 여러 채널을 통해 콜 접속을 제공합니다.
전화 참여자는 제공된 링크를 통해 사전 등록해야 하며, 이를 통해 전화 접속 정보와 고유한 인증 정보를 받게 됩니다. 컨퍼런스 콜 녹음은 행사 후 회사의 투자자 페이지에서 다시 들을 수 있습니다.
Emergent BioSolutions (NYSE:EBS) a programmé sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 pour le 6 août 2025 à 17h00 ET. La société offrira un accès à l'appel via plusieurs canaux, y compris un webcast en direct disponible sur leur page Investisseurs.
Les participants par téléphone doivent se préinscrire via un lien fourni afin de recevoir les informations de connexion et des identifiants uniques. Une rediffusion de la conférence sera disponible sur la page Investisseurs après l'événement.
Emergent BioSolutions (NYSE:EBS) hat seine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2025 für den 6. August 2025 um 17:00 Uhr ET angesetzt. Das Unternehmen stellt den Zugang zur Telefonkonferenz über mehrere Kanäle bereit, darunter ein Live-Webcast auf der Investorenseite.
Telefonteilnehmer müssen sich über einen bereitgestellten Link vorab registrieren, um Einwahlinformationen und individuelle Zugangsdaten zu erhalten. Eine Aufzeichnung der Telefonkonferenz wird nach der Veranstaltung auf der Investorenseite verfügbar sein.
- None.
- None.
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025.
Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When will Emergent BioSolutions (EBS) report Q2 2025 earnings?
How can investors join the Emergent BioSolutions Q2 2025 earnings call?
Will there be a replay available for Emergent BioSolutions Q2 2025 earnings call?
Do I need to register in advance for Emergent BioSolutions' Q2 earnings call?
